Background: We previously demonstrated that patients with painful hematologic tumors were more likely to experience pain response after palliative radiotherapy (RT) than those with painful solid tumors. However, it is unknown whether change in pain interference differs between these two tumor types. In the present study, we carried out a secondary analysis of our previous prospective observational study to investigate this matter. Methods: From patients undergoing palliative RT to treat painful tumors, Brief Pain Inventory data were collected at the start of RT and at the 1-, 2-, and 3-month follow-ups. The Mann-Whitney U test was used to compare changes in pain interference score from baseline between the two groups. Results: Of the 237 patients, 203 (86%) had solid and 34 (14%) had hematologic index tumors planned to receive RT. At baseline, the groups did not differ significantly in terms of pain score, analgesic use, or pain interference score. At the 1-, 2-, and 3-month follow-ups, the changes in pain interference score from baseline did not differ significantly between the two groups. In both groups, all seven pain interference items, other than sleep in patients with hematologic tumors at the 2-month follow-up, were significantly improved (P < 0.05). Conclusions: The two groups showed comparable benefit from RT in terms of improvement in pain interference. Patients with tumor-related pain should be offered the option of palliative RT, irrespective of whether the painful tumor is solid or hematologic.
Introduction
Palliative radiotherapy (RT) is an important treatment for pain caused by tumors (1) , particularly bone metastases, from which most available evidence about palliative RT is derived (2, 3) . However, it is unclear whether the pain-palliating effects of RT differ among tumor types. In our previous study investigating the predictors of pain palliation after RT, patients with painful hematologic tumors were more likely to experience pain response after RT than those with painful solid tumors (4) . However, when evaluating pain treatment, improved interference in daily activity, rather than simply pain reduction, is a more relevant endpoint that better reflects the true benefits of the treatment (5) . Thus, in the present study, which constitutes a secondary analysis of our previously published prospective observational study (4), we asked whether hematologic tumors differ from solid tumors in terms of improvement in pain interference after RT.
Materials and methods

Patients and study design
The original study (4) involved 302 analyzable patients who were scheduled for RT to treat their painful tumors. Of these, 237 patients were treated with palliative intent and were therefore analyzed in the present study (Fig. 1) . In this regard, RT was defined as palliative if the primary purpose of the treatment was pain relief, or if the radiation field did not cover all tumors identified by diagnostic imaging. This secondary study was approved by the institutional review boards of the participating centers, and written informed consent was obtained from all enrolled patients in the primary study.
Evaluation
The method of patient evaluation was reported in detail in the previous study (4) . Briefly, at baseline, the treating radiation oncologist identified the index pain caused by the irradiated tumor using physical examination and diagnostic imaging. The treating radiation oncologist recorded whether the index pain had a neuropathic component according to the definition provided by the International Association for the Study of Pain -Neuropathic Pain Special Interest Group (6) . Patients with definite and probable neuropathic pain were recorded as having a neuropathic component (7) . We used the Brief Pain Inventory (BPI) short form (Japanese version), which is an 11-point scale (0 to 10), to evaluate pain intensity and pain interference in the patient's life (8) . The patients reported their worst pain (in terms of the index pain) in the previous 3 days. Pain interference was evaluated on seven subscales: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. We collected the BPI data and analgesic data at baseline, as well as at 1, 2 and 3 months (±7 days) after the start of RT. Pain response was assessed using the International Consensus Endpoint for clinical trials in bone metastases (9) . Patients who underwent RT for painful tumors were categorized as either responders or nonresponders; responders were those who experienced complete or partial responses, whereby complete response was defined as an index pain score of 0, with no increase in the daily oral morphine equivalent dose (OMED) (9) . A partial response was defined as a reduction in pain score of ≥2, without any increase in daily OMED, or a reduction in analgesic use of ≥25%, without any increase in pain score. Pain progression was defined as an increase of ≥2 in index pain score, with no reduction in daily OMED, or as an increase of ≥25% in daily OMED, with no decrease in pain score. Any response that fell outside these three categories was defined as intermediate.
Statistical analysis
The patients' characteristics were analyzed using the Mann-Whitney U test for continuous variables and Fisher's exact test for categorical variables. Eastern Cooperative Oncology Group (ECOG) performance status (≤1 vs. >1) and worst pain score at baseline (≤7 vs. >7) were treated as binary variables; age and total radiation dose were treated as continuous variables. The patients' baseline pain interference scores, as well as the changes in their pain interference scores from baseline to each follow-up, were analyzed using the Mann-Whitney U test. Pain response rates were compared between the patients with solid tumors and those with hematologic tumors using Fisher's exact test. All tests were two-tailed; P values < 0.05 were considered statistically significant. We did not adjust for multiple comparisons in this exploratory study. All statistical analyses were performed using SPSS software version 24 (IBM SPSS, Armonk, NY, USA).
Results
Patients
Of the 237 patients who were scheduled to undergo palliative RT, 203 (86%) had solid and 34 (14%) had hematologic index tumors ( Table 1 ). The irradiated solid tumors (n = 203) comprised 26 primary tumors, 25 lymph node metastases, 131 hematogenous metastases, including bone metastases, and 21 others. The primary sites of the solid tumors (n = 203) were the lung (n = 69), gastrointestinal system (n = 50), gynecological system (n = 25), head and neck (n = 15), urogenital system (n = 15), breast (n = 14), skin (n = 4), soft tissues (n = 4), and others (n = 7). The hematologic tumors (n = 34) comprised myeloma (n = 18), plasmacytoma (n = 5), lymphoma (n = 8), and others (n = 3). The patients with hematologic tumors had worse ECOG performance status than those with solid tumors (Table 1 ). There was no significant difference in pain score, analgesic use, or the seven pain interference scores between the two groups at baseline ( Table 2 ). 
Pain response
At baseline and at the 1-, 2-, and 3-month follow-ups, the mean worst pain scores were 7.0, 3.6, 2.9 and 2.4, respectively, in patients with solid tumors; the equivalent values were 7.2, 2.7, 2.6 and 1.6 in patients with hematologic tumors (Fig. 2) . In patients with solid and hematologic tumors, the per-protocol pain response rates were, respectively, 47% and 74% after 1 month (P = 0.012), 53% and 67% after 2 months (P = 0.27), and 51% and 74% after 3 months (P = 0.065; Table 3 ). The intention-to-treat pain response rates of all 203 solid and 34 hematologic tumors were, respectively, 40% and 59% after 1 month, 38% and 47% after 2 months, and 28% and 50% after 3 months.
Opioid analgesic use
At baseline and at the 1-, 2-and 3-month follow-ups, the mean daily OMEDs were 46.0, 41.4, 36.7 and 35.1 mg, respectively, in patients with solid tumors; the equivalent values were 31.7, 30.9, 33.4 and 39.1 mg in patients with hematologic tumors (Fig. 2) .
Brief Pain Inventory pain interference scores
At baseline and the 1-, 2-and 3-month follow-ups, the patients with solid tumors had mean pain interference scores of 5.7, 3.0, 2.7 and 2.0 for general activity, 5.4, 2.9, 2.5 and 2.0 for mood, 5.0, 2.7, 2.3 and 2.0 for walking ability, 5.8, 3.0, 2.8 and 2.3 for normal work, 4.1, 1.6, 1.6 and 1.6 for relations with other people, 4.3, 2.0, 2.3 and 1.9 for sleep, and 5.7, 2.7, 2.7 and 2.0 for enjoyment of life, respectively (Fig. 2) . At baseline and at the 1-, 2-and 3-month follow-ups, patients with hematologic tumors had mean pain interference scores of 5.3, 1.5, 2.1 and 1.2 for general activity, 4.9, 0.8, 1.8 and 0.6 for mood, 5.5, 1.7, 2.1 and 0.6 for walking ability, 5.8, 1.9, 1.7 and 0.7 for normal work, 4.0, 0.2, 0.9 and 0.4 for relations with other people, 3.6, 1.2, 1.3 and 0.5 for sleep, and 5.4, 1.3, 1.4 and 0.6 for enjoyment of life, respectively. The change in the pain interference scores from baseline did not differ significantly between the two groups (Table 4) . In both groups, the 95% confidence intervals suggested that all seven pain interference items, other than sleep in patients with hematologic tumors at the 2-month follow-up, were significantly improved after RT (Table 4 ).
Discussion
We found that the change in pain interference after RT did not differ between patients with solid and those with hematologic tumors. Both groups showed significant improvements in pain interference. The patients with hematologic tumors experienced higher rates of pain response shortly after palliative RT than those with solid tumors.
Both groups showed improvement in pain interference after palliative RT. The patients with hematologic tumors seem to have had slightly greater reductions in pain interference scores than those with solid tumors (Fig. 2) , although these differences were not statistically significant. Both patients with solid tumors and those with hematologic tumors should be offered the option of palliative RT. The pain response rate in patients with hematologic tumors 1 month after RT was significantly higher than that in patients with solid tumors. This high response rate shortly after RT is consistent with past studies investigating the effects of palliative RT on painful hematologic tumors (10) (11) (12) (13) . It follows that the optimum time point to assess the effects of palliative RT may differ between hematologic and solid tumors.
Although many of the effects of RT on pain intensity and pain interference occurred during the first month after RT initiation, the pain intensity, and some of the pain interference scores, continued to decrease until the 3-month follow-up (Fig. 2) . In addition, in both groups, the complete response rates increased throughout the 3-month follow-up (Table 3) .
Therefore, although patients with a relatively short life expectancy may still be candidates for palliative RT, those with a life expectancy of ≥3 months would be more likely to derive sufficient benefits. For this reason, for palliation of tumor-related pain, intervention with RT should be carried out early.
Although RT has been used to treat various painful tumors (13) (14) (15) , most existing evidence on pain palliation by RT has come from studies on painful bone metastases. Studies on palliative RT to treat painful tumors other than bone metastases are limited (14, (16) (17) (18) (19) (20) . In the present study, patients with various painful tumors experienced improvement in pain interference after palliative RT. However, we could not analyze the individual tumor types in the present study, because the sample size was too small. Therefore, further larger studies involving different painful tumors are needed.
The main limitations of the present study, in terms of statistical power, were the small sample size and relatively high attrition rate. The wide confidence intervals in the analysis of pain interference changes in patients with hematologic tumors suggests that we may have missed some clinically meaningful differences between the two groups. The results of the present study should be confirmed in larger studies.
In summary, in the present secondary analysis of a prospective observational study, RT conferred comparable improvements in pain interference in patients with solid and hematologic painful tumors. Patients with tumor-related pain should be offered the option of palliative RT, irrespective of whether the painful tumor is solid or hematologic.
